Definition
The Gastrografin Challenge is a diagnostic and therapeutic test used primarily in patients with suspected small bowel obstruction (SBO). It involves administering Gastrografin, a water-soluble iodinated contrast agent, to assess and potentially treat the obstruction.
Mechanism & Role
- Diagnostic: Helps differentiate partial vs complete SBO based on whether contrast passes into the colon on imaging.
- Therapeutic: Gastrografin is hyperosmolar → draws water into the bowel lumen → may help relieve partial obstruction.
Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium)
- Class: Water-soluble, iodine-based radiopaque contrast
- Osmolarity: Very high (~1900 mOsm/L)
- Administration: Usually 100 mL orally or via NG tube, followed by an abdominal X-ray at 4–24 hours
Interpreting Results
- Contrast reaches colon within 24 hrs: Suggests partial SBO, likely to resolve non-surgically
- Contrast does not reach colon: Suggests complete SBO, likely needs surgery
Clinical Pharmacist Considerations
| Parameter | Details |
|---|---|
| Monitoring | Electrolytes, signs of perforation, hydration status |
| Adverse Effects | Nausea, vomiting, aspiration risk, dehydration (due to hyperosmolarity) |
| Contraindications | Suspected bowel perforation, aspiration risk, iodine allergy |
| Counseling | Ensure patient is NPO before test; warn about diarrhea and GI discomfort |
| IV vs Oral | Oral/NG preferred for this test; not given IV for SBO evaluation |